Content about Bimatoprost

August 14, 2012

Target’s in-store health clinics recently started offering consultations for eyelash lengthening and the treatment of hyperpigmentation of the skin and unwanted facial hair, according to a local news report.

MINNEAPOLIS — Target’s in-store health clinics recently started offering consultations for eyelash lengthening and the treatment of hyperpigmentation of the skin and unwanted facial hair, according to a local news report.

April 3, 2012

Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

PARSIPPANY, N.J. — Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

Watson announced that it had filed with the Food and Drug Administration for generic versions of Allergan's Lumigan and Latisse (bimatoprost) ophthalmic solution. The products contain the same active ingredient in the 0.01% and 0.03% strengths, respectively, and are used to reduce pressure within the eye in patients with open-angle glaucoma or ocular hypertension.

February 1, 2011

Thanks to technological innovations within mascara, the category has driven sales of eye makeup, and looking forward, mascara formulas that are infused with eyelash-enhancing treatments and packaging that offers greater customization not only will volumize lashes but also sales at retail.


Thanks to technological innovations within mascara, the category has driven sales of eye makeup, and looking forward, mascara formulas that are infused with eyelash-enhancing treatments and packaging that offers greater customization not only will volumize lashes but also sales at retail.


September 6, 2010

Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

August 31, 2010

Allergan's optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the...

IRVINE, Calif. Allergan's optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the drug maker said Wednesday.

Lumigan 0.01% (bimatoprost ophthalmic solution) is a first-line therapy indicated for the reduction of elevated intraocular pressure with open-angle glaucoma or ocular hypertension, Allergan said. Lumigan 0.01% will be available in fourth quarter 2010 as the newest addition to Allergan’s comprehensive glaucoma portfolio.

 

March 8, 2010

RediClinic, which operates 22 retail health clinics inside select H-E-B stores in the Greater Houston...

HOUSTON RediClinic, which operates 22 retail health clinics inside select H-E-B stores in the Greater Houston and Austin area, now is offering Latisse, an FDA-approved prescription treatment to grow lashes.

Latisse is a prescription treatment for hypotrichosis used to grow eyelashes. Eyelash hypotrichosis is another name for not having enough eyelashes or eyelashes that are inadequate. The topical solution must be applied each night on the skin of the upper eyelid margins at the base of the eyelashes. Results are gradual and peak after 12 to 16 weeks.

January 7, 2008

Looking to untangle itself from FDA conflicts and a patent dispute with drug maker Allergan,...

November 18, 2007

The Food and Drug Administration has announced that nearly 13,000 tubes of Age Intervention Eyelash...